R E Mendes

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. doi request reprint Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)
    R E Mendes
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, 52317, USA
    Eur J Clin Microbiol Infect Dis . 2017
  2. doi request reprint Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents
    Rodrigo E Mendes
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    J Glob Antimicrob Resist 8:28-32. 2016
  3. doi request reprint Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, United States Electronic address
    J Glob Antimicrob Resist 3:36-39. 2015
  4. ncbi request reprint Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 71:3453-3458. 2016
  5. pmc In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:4407-11. 2016
  6. doi request reprint Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 71:1860-5. 2016
  7. pmc Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:3817-20. 2016
  8. pmc β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:1328-35. 2015
  9. pmc Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 54:204-7. 2016
  10. pmc Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:5595-601. 2015

Detail Information

Publications67

  1. doi request reprint Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014)
    R E Mendes
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, 52317, USA
    Eur J Clin Microbiol Infect Dis . 2017
    ..aureus, regardless of the susceptibility phenotype or demographic characteristics (100.0% susceptible), and supports the sought-after subsequent indications...
  2. doi request reprint Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents
    Rodrigo E Mendes
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA Electronic address
    J Glob Antimicrob Resist 8:28-32. 2016
    ..Oritavancin demonstrated in vitro potencies that were similar to or greater than those of comparators against this recent collection of streptococci, including drug-resistant subsets, from European and adjacent countries...
  3. doi request reprint Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, United States Electronic address
    J Glob Antimicrob Resist 3:36-39. 2015
    ..This study provides new baseline MIC results for telavancin and confirms the spectrum and potency of telavancin against less commonly encountered Gram-positive species...
  4. ncbi request reprint Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 71:3453-3458. 2016
    ..The objective of this study was to evaluate the prevalence and in vitro susceptibility of enterococci and VRE among bloodstream infections in European and US hospitals over time...
  5. pmc In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:4407-11. 2016
    ..These data support the clinical development of lefamulin for the treatment of community-acquired respiratory tract infections. ..
  6. doi request reprint Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 71:1860-5. 2016
    ..The objective of this study was to report the linezolid in vitro activity observed during the Zyvox(®) Annual Appraisal of Potency and Spectrum (ZAAPS) programme for 2014...
  7. pmc Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:3817-20. 2016
    ..All linezolid-resistant isolates were inhibited by oritavancin at ≤0.12 μg/ml. These results confirmed the absence of cross-resistance between linezolid and oritavancin in staphylococci and enterococci. ..
  8. pmc β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 60:1328-35. 2015
    ..8% versus 86.7%, respectively). The efficacy of ceftazidime-avibactam was similar to that of carbapenems for treatment of cUTI and cIAI caused by ESBL organisms...
  9. pmc Performance of BD Max StaphSR for Screening of Methicillin-Resistant Staphylococcus aureus Isolates among a Contemporary and Diverse Collection from 146 Institutions Located in Nine U.S. Census Regions: Prevalence of mecA Dropout Mutants
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 54:204-7. 2016
    ..However, six of these MSSA isolates had the mecA gene confirmed by PCR and sequencing (99.8% sensitivity; 898/900). Overall, 7.1% (64/900) of MSSA isolates showed results compatible with a mecA dropout genotype. ..
  10. pmc Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:5595-601. 2015
    ....
  11. pmc Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 53:2727-30. 2015
    ..faecalis were responsible for major and minor errors. These results support the use of vancomycin to infer telavancin susceptibility among indicated pathogens, except VISA, which should be tested for telavancin susceptibility. ..
  12. doi request reprint Update of the telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2013), when applying the revised susceptibility testing method
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 81:275-9. 2015
    ..015 μg/mL, except for Streptococcus agalactiae (MIC50, 0.03 μg/mL). These in vitro results obtained by the recently approved susceptibility testing method establish a new benchmark of telavancin activity worldwide...
  13. pmc Update on linezolid in vitro activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:2454-7. 2015
    ..Linezolid inhibited all enterococci and streptococci at ≤2 μg/ml, except for one Enterococcus faecium strain (MIC, 8 μg/ml; G2576T [Escherichia coli numbering] mutation). ..
  14. pmc Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:1811-4. 2015
    ..06 μg/ml) values 2-fold higher than those of isolates with lower MIC results (MIC50, 0.03 μg/ml). However, telavancin had MIC90 and MIC100 results of 0.06 and 0.12 μg/ml (100% susceptible), respectively, regardless of the MRSA subset. ..
  15. doi request reprint Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Antimicrob Chemother 70:498-504. 2015
    ..To assess oritavancin activity in vitro against clinically relevant Gram-positive pathogens causing skin and soft-tissue infections (SSTIs) in European and US hospitals...
  16. doi request reprint Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA Electronic address
    Diagn Microbiol Infect Dis 80:19-25. 2014
    ..e. ≥ 4 μg/mL) and oral breakpoints (i.e. ≥ 0.12 μg/mL), respectively. Ceftaroline was the most potent agent tested based on MIC50 and MIC90 values (≤ 0.015 and 0.12 μg/mL, respectively) for both time periods...
  17. pmc Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:702-6. 2015
    ..e., 0.03 μg/ml). This study reestablishes the telavancin spectrum of activity against isolates recovered from the United States (2011-2012) using the revised broth microdilution method...
  18. doi request reprint Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA Electronic address
    Drug Resist Updat 17:1-12. 2014
    ..These events will likely establish a new chapter for this successful class of antimicrobial agents. ..
  19. pmc Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 58:4923-7. 2014
    ..S. Census regions. Ceftaroline (MIC50/90, 0.12/0.25 μg/ml) remained active (≥ 96.8% susceptible) when tested against these less susceptible isolates...
  20. doi request reprint Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 69:1579-81. 2014
    ..To assess the oritavancin spectrum and activity against 2811 rarer species of coagulase-negative staphylococci (CoNS), streptococci and other Gram-positive species...
  21. doi request reprint Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 69:1582-8. 2014
    ..Moreover, to provide molecular characterization for associated resistance mechanisms and epidemiological typing...
  22. pmc Streptococcus sanguinis isolate displaying a phenotype with cross-resistance to several rRNA-targeting agents
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 51:2728-31. 2013
    ..The S. sanguinis strain had mutations in the 23S rRNA (T2211C, T2406C, G2576T, C2610T) and an amino acid substitution (N56D) in L22 and exhibited cross-resistance to ribosome-targeting agents. ..
  23. pmc Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 57:2923-8. 2013
    ..The cfr-carrying plasmid detected in the remaining S. aureus isolate (7.9 kb) was distinct and showed the highest identity to the chromosomal cfr integrate found in the chromosomal DNA of a Proteus vulgaris isolate from a pig in China...
  24. pmc Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 50:3694-702. 2012
    ..The USA300 rate corroborates previous reports describing increased prevalence of USA300 strains causing invasive infections. The prevalence of hVISA was elevated in Asia, and these strains were associated with CC5...
  25. pmc Molecular epidemiology of Staphylococcus epidermidis clinical isolates from U.S. hospitals
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:4656-61. 2012
    ..Interestingly, these 23S rRNA mutants also had L3 alterations, which may act synergistically or in a compensatory manner to minimize the fitness cost while providing survival advantages under selective pressure...
  26. doi request reprint Oritavancin microbiologic features and activity results from the surveillance program in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Clin Infect Dis 54:S203-13. 2012
    ..25 μg/mL. In vitro results for oritavancin indicate wide potential use against Gram-positive pathogens...
  27. pmc Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 56:1639-42. 2012
    ..03 and 0.06 μg/ml). Oritavancin exhibited good in vitro potency against this collection of organisms, including vancomycin-resistant enterococci...
  28. doi request reprint Assessment of linezolid resistance mechanisms among Staphylococcus epidermidis causing bacteraemia in Rome, Italy
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:2329-35. 2010
    ..Isolates also showed elevated MICs of macrolide, lincosamide and streptogramin (MLS) compounds, which were investigated...
  29. doi request reprint Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA Hospitals (2007-2009)
    Rodrigo E Mendes
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 72:113-7. 2012
    ..12 μg/mL) against other streptococci, regardless of resistance to other drugs. This assessment reveals potent activity of telavancin against Gram-positive isolates collected from USA hospitals with no evidence of emergence of resistance...
  30. doi request reprint Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA, USA
    Diagn Microbiol Infect Dis 71:177-80. 2011
    ..Strains were wild type for L3 and L4, but positive for vga(A) and tet(M). vga(A) was plasmid-located (ca. 24-kb) and demonstrated mobilization genes upstream and a transposase belonging to the IS3 family located downstream...
  31. doi request reprint Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 71:93-7. 2011
    ..aureus infections in Europe, including those infections caused by strains with decreased susceptibility to vancomycin and/or teicoplanin...
  32. doi request reprint Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009)
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 68:307-11. 2010
    ..0% of those displaying multidrug resistance. Other tested agents showed limited activity and a significant (P < 0.001) trend toward decreased susceptibility during the study period...
  33. doi request reprint Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 63:55-9. 2009
    ..isolates recovered from medical centres in the Asia-Pacific (APAC) region...
  34. doi request reprint Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008)
    Rodrigo E Mendes
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 36:374-9. 2010
    ..Based upon MIC(90) values, telavancin demonstrated potent in vitro activity against a contemporary (2007-2008) collection of Staphylococcus spp. recovered from nearly 30 European medical centres...
  35. pmc In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 54:2704-6. 2010
    ..These data show a potent activity of telavancin tested against a current global collection of S. aureus...
  36. pmc Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid
    Rodrigo E Mendes
    JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA
    J Clin Microbiol 48:568-74. 2010
    ....
  37. ncbi request reprint Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 60:433-6. 2008
    ..4% belonged to the USA300-0114 clone and 94.7% were PVL positive. Tigecycline showed in vitro activity comparable with other highly active parenteral agents and represents an option for treating complicated infections caused by CA-MRSA...
  38. doi request reprint Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Microb Drug Resist 15:245-9. 2009
    ..In conclusion, daptomycin was the most active agent tested against this collection of gram-positive clinical organisms and ribosomal target mutations comprised the main resistance mechanism against linezolid...
  39. doi request reprint Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy
    R E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 15:588-92. 2009
    ..baumannii to cause epidemic/endemic outbreaks and also to acquire various resistance genes circulating in the hospital environment...
  40. doi request reprint Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 63:415-25. 2009
    ..Doripenem could represent a valuable choice for broad-spectrum coverage of contemporary Enterobacteriaceae isolates with widespread resistance mechanisms...
  41. ncbi request reprint Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections
    M A Pfaller
    JMI Laboratories, North Liberty, IA 52317, USA
    J Chemother 22:304-11. 2010
    ..03/0.06 mg/l; 100.0% susceptible). These in vitro data document the activity of telavancin against contemporary Gram-positive isolates and support its clinical use for the treatment of cSSSI caused by the indicated pathogens...
  42. pmc First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States
    Rodrigo E Mendes
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 52:2244-6. 2008
    ..We describe the first detection of cfr-mediated linezolid resistance in Staphylococcus aureus and Staphylococcus epidermidis recovered from human infection cases monitored during the 2007 LEADER Program...
  43. doi request reprint Dissemination and genetic context analysis of bla(VIM-6) among Pseudomonas aeruginosa isolates in Asian-Pacific Nations
    M Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    Clin Microbiol Infect 16:186-9. 2010
    ..These two integrons, bla(VIM-6) was located in the first position, followed by bla(OXA-10) and aacA4. The 5-kb integrons also harboured aadA1 and a 331-bp open reading frame encoding a putative efflux pump...
  44. ncbi request reprint Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries
    J E Ross
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
    J Chemother 23:71-6. 2011
    ..In conclusion, the ZAAPS program surveillance confirmed high, sustained levels of linezolid activity from 2002-2009 and without evidence of MIC creep or escalating resistance in gram-positive pathogens across monitored european nations...
  45. pmc Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa 52317, USA
    Antimicrob Agents Chemother 55:1274-8. 2011
    ..Multiple pulsed-field gel electrophoresis patterns and clonal dissemination within and among sites were observed. Isolates producing NDM-1 were disseminated in Indian health care facilities as early as 2006...
  46. ncbi request reprint Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Helio S Sader
    The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
    Int J Antimicrob Agents 25:57-61. 2005
    ..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
  47. doi request reprint Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007)
    Mariana Castanheira
    JMI Laboratories, North Liberty, Iowa, USA
    Microb Drug Resist 14:211-6. 2008
    ..S. hospitals participating in the MYSTIC Program in 2007...
  48. doi request reprint United States resistance surveillance results for linezolid (LEADER Program for 2007)
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA Tufts University School of Medicine, Boston, MA 02111, USA
    Diagn Microbiol Infect Dis 62:416-26. 2008
    ..aureus and Staphylococcus epidermidis strains from Arizona and Ohio. The LEADER Program appears to be an effective and sensitive surveillance tool to detect novel resistance phenotypes and genotypes...
  49. doi request reprint TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 63:716-20. 2009
    ..In this study, single-step mutation frequencies, passaging and the activity of TR-700 were tested against a worldwide collection of linezolid-non-susceptible organisms and matched controls...
  50. doi request reprint Spectrum of activity, mutation rates, synergistic interactions, and the effects of pH and serum proteins for fusidic acid (CEM-102)
    Douglas J Biedenbach
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 66:301-7. 2010
    ..8 x 10(-8) for 16 x MIC. In conclusion, these in vitro results for fusidic acid tested against contemporary strains confirm a persisting antimicrobial spectrum, especially against staphylococci and some other Gram-positive species...
  51. doi request reprint Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008)
    Mariana Castanheira
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:1353-8. 2010
    ..To determine fusidic acid resistance rates (MICs of > or = 2 mg/L) and the prevalence of fusidic acid resistance mechanisms among Staphylococcus spp. collected from European countries (2008)...
  52. doi request reprint Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results
    Shannon D Putnam
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 67:359-68. 2010
    ..faecalis (MIC(50/90), 0.25/0.5 microg/mL) and E. faecium (MIC(50/90), 0.06/0.25 microg/mL). These in vitro results show continued activity for telavancin, which represents an important alternative available for treating cSSSI...
  53. doi request reprint Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program
    Douglas J Biedenbach
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 68:459-67. 2010
    ..48%) having the mobile cfr gene. The results of this study demonstrate that linezolid continues to be effective in vitro against MDR pathogens, and the resistance rates appear stable...
  54. doi request reprint Linezolid surveillance program results for 2008 (LEADER Program for 2008)
    David J Farrell
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:392-403. 2009
    ..However, there was evidence of cfr persistence with the S. epidermidis strain. The LEADER Program continues to be an effective and sensitive surveillance tool to detect and monitor novel oxazolidinone resistance phenotypes and genotypes...
  55. doi request reprint Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study
    Ronald N Jones
    JMI Laboratories, North Liberty, IA 52317, USA
    J Antimicrob Chemother 65:iv17-31. 2010
    ..To assess the spectrum and potency of ceftaroline, a novel anti-methicillin-resistant staphylococcal cephalosporin, against a 2008 surveillance collection of clinical isolates from patients in the USA and Europe...
  56. pmc Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012
    D J Farrell
    JMI Laboratories, North Liberty, Iowa, USA
    Antimicrob Agents Chemother 59:2432-4. 2015
    ..5 μg/ml, including the two most prevalent macrolide-resistant serotypes (19A and 35B). These data support the continued clinical development of solithromycin for the treatment of multidrug-resistant CABP. ..
  57. ncbi request reprint Ability of Latin America laboratories to detect antimicrobial resistance patterns: experience of the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Rodrigo E Mendes
    Special Laboratory of Clinical Microbiology Federal University of São Paulo, SP, Brazil
    Braz J Infect Dis 7:282-9. 2003
    ....
  58. pmc First isolation of bla(VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program
    Rodrigo E Mendes
    Antimicrob Agents Chemother 48:1433-4. 2004
  59. pmc Emergence of the extended-spectrum beta-lactamase GES-1 in a Pseudomonas aeruginosa strain from Brazil: report from the SENTRY antimicrobial surveillance program
    Mariana Castanheira
    Antimicrob Agents Chemother 48:2344-5. 2004
  60. pmc Integron carrying a novel metallo-beta-lactamase gene, blaIMP-16, and a fused form of aminoglycoside-resistant gene aac(6')-30/aac(6')-Ib': report from the SENTRY Antimicrobial Surveillance Program
    Rodrigo E Mendes
    Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 48:4693-702. 2004
    ..36 microM(-1) . s(-1)). This report further emphasizes the spread of metallo-beta-lactamase genes and their close association with various aminoglycoside resistance genes...
  61. ncbi request reprint Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Ana C Gales
    Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
    Diagn Microbiol Infect Dis 44:313-8. 2002
    ....
  62. pmc Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital
    Rodrigo E Mendes
    Laboratório Especial de Microbiologia Clínica and Laboratório ALERTA, Division of Infectious Disease, Federal University of Sao Paulo, Sao Paulo, Brazil
    Antimicrob Agents Chemother 51:2611-4. 2007
    ..This report describes the ability of nonfermentative nosocomial pathogens to acquire and disseminate antimicrobial resistance determinants...
  63. pmc Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene
    Rodrigo E Mendes
    Antimicrob Agents Chemother 52:798-9. 2008
  64. pmc Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates
    Renata C Picão
    Laboratório ALERTA, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
    J Clin Microbiol 46:2028-37. 2008
    ..Our results indicate that both phenotypic methods to detect MBL-producing isolates should be based on the genera to be tested, regardless of the enzyme produced by such isolates, as well as on the local prevalence of MBL producers...
  65. doi request reprint Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates
    Rodrigo E Mendes
    Clin Infect Dis 46:1324-6. 2008
  66. pmc Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis
    Rodrigo E Mendes
    Division of Infectious Diseases, Federal University of Sao Paulo, Rua Leandro Dupret, 188, Sao Paulo, SP, Brazil CEP 04025 010
    J Clin Microbiol 45:544-7. 2007
    ..This assay could be suitable for identification of MbetaL-producing gram-negative bacteria by molecular diagnostic laboratories...
  67. pmc Prevalence of and molecular basis for tuberculosis drug resistance in the Republic of Georgia: validation of a QIAplex system for detection of drug resistance-related mutations
    Medea Gegia
    Georgian Foundation against Tuberculosis and Lung Diseases, National Center of Tuberculosis and Lung Diseases, Tbilisi, Georgia, USA
    Antimicrob Agents Chemother 52:725-9. 2008
    ..05). Simultaneous detection of 24 common drug resistance-related mutations provides a molecular tool for studying and monitoring M. tuberculosis resistance mechanism and epidemiology...